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Due to its pivotal role in the growth factor-mediated tumour cell migration, the adaptor protein phospholipase C-g1 (PLC-g1) is an
appropriate target to block ultimately the spreading of EGFR/c-erbB-2-positive tumour cells, thereby minimising metastasis formation.
Here, we present an approach to block PLC-g1 activity by using protein-based PLC-g1 inhibitors consisting of PLC-g1 SH2 domains,
which were fused to the TAT-transduction domain to ensure a high protein transduction efficiency. Two proteins were generated
containing one PLC-g1-SH2-domain (PS1-TAT) or two PLC-g1-SH2 domains (PS2-TAT). PS2-TAT treatment of the EGFR/c-erbB-
2-positive cell line MDA-HER2 resulted in a reduction of the EGF-mediated PLC-g1 tyrosine phosphorylation of about 30%,
concomitant with a complete abrogation of the EGF-driven calcium influx. In addition to this, long-term PS2-TAT treatment both
reduces the EGF-mediated migration of about 75% combined with a markedly decreased time locomotion of single MDA-HER2 cells
as well as decreases the proliferation of MDA-HER2 cells by about 50%. Due to its antitumoral capacity on EGFR/c-erbB-2-positive
breast cancer cells, we conclude from our results that the protein-based PLC-g1 inhibitor PS2-TAT may be a means for novel
adjuvant antitumour strategies to minimise metastasis formation because of the blockade of cell migration and proliferation.
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The primary cause of death in cancer is not attributed to the
primary tumour growth but rather to the formation of metastases
at distant organ sites. A key role in this process is the ability of
single tumour cells or tumour cell clusters to become motile,
thereby detaching from the primary tumour and start to migrate
through the surrounding extracellular matrix. A decisive step in
the initiation of migration of epidermal growth factor receptor
(EGFR)/c-erbB-2-positive breast cancer cells has been attributed to
the specific phosphorylation of tyrosine residue 1248 of c-erbB-2
via EGFR, thereby modulating the time course of the adaptor
protein phospholipase C-g1 (PLC-g1) (Dittmar et al, 2002).
Epidermal growth factor receptor and c-erbB-2 belong to the erbB
receptor family and they are activated via ligand-induced
homodimerisation as well as heterodimerisation (Alroy and
Yarden, 1997), whereby c-erbB-2 is the preferred heterodimerisa-
tion partner of all erbB receptors (Graus-Porta et al, 1997).
Epidermal growth factor (EGF)-induced PLC-g1 activation con-
tributes to the engagement of actin-modifying enzymes including
gelsolin (Chen et al, 1996), resulting in the rearrangement of the
actin cytoskeleton, thereby promoting cell migration by increasing
the fraction of cells in a motility-permissive morphology (Wells
et al, 1999). The relationship between EGFR/c-erbB-2 heterodimer
signalling and gelsolin activation in breast cancer cells has been
called the ‘master switch’ hypothesis (Brandt et al, 1999; Thor et al,
2001). Epidermal growth factor receptor/c-erbB-2 heterodimers are
constitutively formed on breast cancer cells, thereby determining a
motogenic phenotype (Brandt et al, 1999) through the above-
mentioned mechanism (Dittmar et al, 2002). In addition to its
participation in overall cell migration, there is evidence that the
directionality of cell migration is also PLC-g1 regulated. This is
regulated via binding of PLC-g1 to phosphatidylinositol-3,4,5-
trisphosphate (PIP3) (Falasca et al, 1998), which in turn is the
product of phosphoinositide 3-kinase (PI-3K) that translocates due
to an EGF-dependent mechanism at the leading edge of the cell
(Piccolo et al, 2002).
Inhibition of PLC-g1 activity due to the expression of a
dominant-negative PLCz molecule or the pharmacological PLC-
g1 inhibitor U73122 resulted in a reduction of the in vitro
invasiveness of breast and prostate tumour cells (Kassis et al,
1999). In addition to this, it was recently shown that the EGF-
induced cell migration of EGFR/c-erbB-2-positive breast cancer
cells, but not of solely EGFR-positive breast cancer cells, could be
blocked with moderate concentrations of the PLC-g1 inhibitor
U73122 (Dittmar et al, 2002). Thus, inhibition of PLC-g1 activity is
an appropriate way to block EGF-driven tumour cell migration and
invasiveness.
However, although Turner et al (1996) reported that intraper-
itoneal administration of U73122 blocks the invasiveness of
prostate cancer cells in a mouse model, the in vivo usage of this
pharmacological inhibitor has to be balanced critically since
U73122 has to be dissolved in organic solvents and tends to
precipitate when transferred to aqueous solutions, thereby losing
its inhibitory activity. In addition to this, it was shown by Rossler
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set al (1998) that U73122 also blocks PLC-b activity. As a
consequence of this, the possible side effects of both U73122 as
well as the organic solvent could not be excluded. In the present
study, we designed an approach to block the EGF-induced cell
migration of EGFR/c-erbB-2-positive breast cancer cells by using
protein-based PLC-g1 inhibitors. These inhibitors consist of either
one (PS1-TAT) or two (PS2-TAT) PLC-g1 SH2 domains that were
fused to the TAT leader motif of the HIV-TAT protein (Nagahara
et al, 1998) to ensure a high transduction efficiency. In this study,
we will provide evidence of the feasibility of protein-based PLC-g1
inhibitors as potent antitumour agents due to their ability to block
PLC-g1 activity efficiently, thereby inhibiting the proliferation as
well as the EGF-induced migration of EGFR/c-erbB-2-positive
breast cancer cells.
MATERIAL AND METHODS
Cells and culture conditions
The breast adenoma carcinoma cell line MDA-MB-468-HER2
(MDA-HER2; EGFR and c-erbB-2 positive) (Dittmar et al, 2002)
was maintained in Leibowitz L-15 media (PAA, Linz, Austria)
supplemented with 10% heat-inactivated foetal calf serum (PAA),
10Uml
 1 penicillin, 10mgml
 1 streptomycin and 400mgml
 1
G418 (Merck BioSciences GmbH, Schwalbach, Germany) in 371C
humidified atmosphere without CO2 supplementation.
Cloning
The PLCg1-(SH2)1 and PLCg1-(SH2)2 DNA sequences were
obtained by RT–PCR of MDA-NEO mRNA (forward primer
(FP): 50-CTA GGT ACC AAG GAG GTC AGC AGC AGC-30, PLC-g1-
(SH2): reverse primer (RP): 50-GAT CGA ATT CAT CTC AAA CTC
ATT ACA GCG-30; PLC-g1-(SH2)2: RP: 50-CTA GAC AAG CTT
CAC TCC TCG TTG ATG GGA TAG CG-30) (all primers: MWG-
Biotech AG, Ebersberg, Germany) and were cloned in-frame into
the bacterial pTAT expression vector (Nagahara et al, 1998) to
produce TAT fusion proteins (Figure 1A). The obtained plasmids
pPLCg1-(SH2)1-TAT (PS1-TAT) and pPLCg1-(SH2)2-TAT (PS2-
TAT), respectively, were transformed into the Escherichia coli
strain XL-1-Blue and subsequently screened by restriction analysis.
Positive recombinants were sequenced additionally prior to
transformation into the E. coli strain BL21(DE3)pLysS. Bacterial
cultures were grown overnight and protein expression was induced
by IPTG treatment for 4–6h followed by sonication in buffer Z
(20mM HEPES (pH 8.0), 8 M urea, 100mM NaCl) containing 20mM
imidazole. The His-tagged fusion proteins were purified using Ni-
NTA-agarose (Qiagen, Hilden, Germany) as described (Nagahara
et al, 1998). After the elution step, the protein solution was
dialysed against PBS using the Slide-A-Lyser dialysis cassette
(Pierce Chemical Co., Rockford, IL, USA). Subsequently, the
protein solution was concentrated in Centricon tubes (Schleicher &
Schuell, Dassel, Germany) and frozen in 10% glycerol at  801C.
Determination of protein transduction efficiency
Dose- and time-dependent uptake of PS1/2-TAT proteins was
determined by flow cytometry (FACSCalibur, Becton Dickenson,
Heidelberg, Germany) using FITC-labelled PS1/2-TAT proteins.
Therefore, PS1/2-TAT fusion proteins were labelled with the dye
Fluorescein by incubating 10mg FITC in 100mM NaCO3 (pH 9)
with 100mg of protein for 2h at room temperature in the dark.
Unbound FITC was removed by dialysing the labelled protein
against PBS. Protein transduction was performed by simply adding
the PS1/2-TAT fusion proteins to the MDA-HER2 cell (6 10
4)
suspension.
Calcium measurements
For the investigation of intracellular calcium changes by treatment
with various concentrations of PS1/2-TAT, MDA-HER2 cells
(6 10
4) were preloaded with the calcium-sensitive fluorescent
dye Fluo3 (Molecular Probes, Leiden, The Netherlands) as
previously described with minor modifications (Lang et al,
2002), and the measurement was started immediately. The value
of the mean Fluo3 fluorescence intensity (MFI) was noted every
10s for a period of 2min. The values were calculated relative to the
initial value t0 that was set to 1.
Immunoprecipitation and Western blot
The analysis of PLC-g1 tyrosine phosphorylation by Western Blot
was performed as previously described (Dittmar et al, 2002) with
minor modifications. MDA-HER2 cells (4 10
6) were pretreated
with PS1/2-TAT (133mM, 30min) prior to EGF treatment
(100ngml
 1, 2min). Phospholipase C-g1 immunoprecipitation
and detection was performed using the specific PLC-g1 antibody
(clone E12; Santa Cruz, Santa Cruz, CA, USA). Phospholipase C-g1
tyrosine phosphorylation was detected using affinity-purified
rabbit polyclonal antibody PLC-g1(pY783) (BioSource, Solingen,
Germany).
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Figure 1 Schematic cloning of PS1/2-TAT proteins and transduction
efficiency. (A) The PLC-g1-(SH2)1 and the PLC-g1-(SH2)2 inserts were
amplified by RT–PCR and cloned in-frame into the pTAT expression
vector. The yielded expression vectors coding for the particular protein
were entitled PS1-TAT and PS2-TAT. (B) The uptake of the recombinant
PS1/2-TAT fusion proteins into MDA-HER2 cells was analysed by flow
cytometry using FITC-labelled PS1/2-TAT fusion proteins. Both PS1-TAT as
well as PS2-TAT rapidly transduced into 100% of MDA-HER2 cells,
achieving maximum intracellular concentration within 5min. This figure
shows a representative histogram plot of MDA-HER2 cells positively
transduced with 2mM PS2-TAT. Untreated MDA-HER2 cells served as a
control.
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The investigation of cell migration using a three-dimensional
collagen lattice assay combined with computer-assisted cell
tracking was performed as previously described (Dittmar et al,
2002). In brief, liquid collagen solution was mixed with 10  MEM,
sodium bicarbonate, MDA-HER2 cells (6 10
4) and the appro-
priate substances to be tested. Cell migration within the three-
dimensional collagen lattices was recorded for at least 12h by
time-lapse video microscopy and subsequently analysed by
computer-assisted cell tracking. For data analysis, 30 cells of each
sample were randomly selected and two-dimensional projections
of the paths were digitised as x/y coordinates in 20min intervals.
XTT proliferation assay
MDA-HER2 proliferation within the presence of PS1/2-TAT
proteins was performed as previously described with minor
modifications (Dittmar et al, 2000). In short, MDA-HER2 cells
(1 10
3) were seeded in quadruplicates in a 96-well microtitre
plate and were permanently treated with PS1/2-TAT (2mM). The
medium containing the appropriate amounts of PS1/2-TAT was
replaced every 48h. Plates were analysed on days 0, 4 and 7 with
XTT reagent, according to the manufacturer’s instruction using a
microplate reader.
Statistical analysis
Statistical analysis was performed using the two-tailed unpaired
Student’s t-test (three independent experiments).
RESULTS
MDA-HER2. cells are successfully transduced with
PLC-c1-SH2-TAT fusion proteins
Two recombinant PLC-g1-(SH2)1/2-TAT fusion proteins were
generated in this study by cloning RT–PCR-amplified PLC-g1-
SH2 DNA sequences into the pTAT expression vector (Figure 1A).
The PLC-g1-(SH2)2-TAT fusion protein (PS2-TAT) contains both
SH2 domains of PLC-g1, whereas the PLC-g1-(SH2)1-TAT fusion
protein (PS1-TAT) was generated by inserting only the N-terminal
SH2 domain of PLC-g1 (Figure 1A) into the pTAT expression
vector. For our studies, we used the MDA-HER2 cell line that is
double positive for EGFR and c-erbB-2 expression (Brandt et al,
1999; Dittmar et al, 2002). The uptake of recombinant PS1/2-TAT
fusion proteins into MDA-HER2 cells was analysed by flow
cytometry using FITC-labelled recombinant PS1/2-TAT fusion
proteins. Both PS1-TAT as well as PS2-TAT rapidly transduced
into 100% of MDA-HER2 cells, achieving maximum intracellular
concentration within 5min. Figure 1b shows a representative result
of MDA-HER2 cells positively transduced with 2mM PS2-TAT. In
order to ensure that all transduced proteins have refolded
correctly, the incubation period was extended to 30min prior to
the start of the desired experiment.
PS2-TAT but not PS1-TAT blocks the EGF-induced
activation of the PLC-c1 signal transduction pathway
in MDA-HER2 cells
In order to investigate whether the recombinant PS1/2-TAT
proteins could inhibit PLC-g1 activation, the EGF-driven calcium
influx was used as a read-out since the influx of calcium is closely
related to PLC-g1 activation (Dittmar et al, 2002). The EGF-
induced calcium influx of MDA-HER2 cells was analysed by flow
cytometry by preloading the cells with the calcium-sensitive
fluorescent dye FLUO-3 prior to PS1/2-TAT (2mM) treatment and
EGF (100ngml
 1) stimulation. Stimulation of MDA-HER2 cells
with 100ngml
 1 EGF resulted in a moderately increased
fluorescence intensity of about 5474% (due to low basal
intracellular calcium levels in this cell line), which was completely
abrogated by PS2-TAT (Figure 2A). Similar results were obtained
with the PLC-g1 inhibitor U73122 (2mM) that served as a control.
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Figure 2 The EGF-induced PLC-g1 activation is blocked by PS2-TAT.
(A) The EGF-induced calcium influx was used as a read-out to study the
inhibitory capacities of the PS1/2-TAT proteins. Treatment of MDA-HER2
cells with PS2-TAT (2mM) but not PS1-TAT (2mM) resulted in a complete
blockade of the EGF (100ngml
 1)-induced calcium influx. U73122 (2mM)
was used as a control. (B) Western Blot analysis was performed to study
the mode of action as to how PS2-TAT blocks PLC-g1 activation. Owing to
the higher number of cells that were used for these experiments, the
amount of PS1/2-TAT was increased accordingly to 133mM. PS2-TAT
treatment resulted in a markedly reduced PLC-g1 tyrosine phosphorylation
in the MDA-HER2 cell line after 2min of EGF (100ngml
 1) stimulation.
PS1-TAT, did not interfere with PLC-g1 tyrosine phosphorylation in MDA-
HER2 cells. (C) Confocal laser scanning microscope analysis revealed a
translocation of PS2-TAT (2mM) proteins towards the plasma
membrane of MDA-HER2 cells after 2min of EGF (100ngml
 1)
stimulation, where it is found to be colocalised with the constitutively
formed EGFR/c-erbB-2 heterodimer (indicated by c-erbB-2 receptor
staining). Bar¼10mm.
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sIn contrast to this, PS1-TAT showed no inhibitory capacity
(Figure 2a). In order to investigate the mode of action as to how
PS2-TAT blocks PLC-g1 activity in MDA-HER2 cells, we deter-
mined the grade of PLC-g1 tyrosine phosphorylation by Western
blot analysis. Owing to the higher number of cells that were used
for Western blot analysis, the amount of PS1/2-TAT was increased
accordingly from 2mM (6 10
4) to 133mM (4 10
6). MDA-HER2
cells were stimulated with 100ngml
 1 EGF for 2min since it was
shown that PLC-g1 tyrosine phosphorylation is highest after this
incubation period (Dittmar et al, 2002). The results we obtained
were congruent with the calcium influx data, indicating that 2mM
PS2-TAT but not 2mM PS1-TAT blocks the EGF-induced PLC-g1
tyrosine phosphorylation in MDA-HER2 cells (Figure 2B). We
estimated a PS2-TAT-dependent reduction of PLC-g1 tyrosine
phosphorylation of about 30%. No differences in PLC-g1 tyrosine
phosphorylation were observed in PS1-TAT-treated MDA-HER2
cells as compared to EGF-treated MDA-HER2 cells. Using confocal
laser scanning microscopy, we observed that EGF (100ngml
 1)
stimulation of PS2-TAT (2mM)-loaded MDA-HER2 cells resulted in
a translocation of the PS2-TAT protein towards the plasma
membrane. Costaining of c-erbB-2, which is part of the
constitutively formed EGFR/c-erbB-2 heterodimer, revealed a
colocalisation of PS2-TAT and the erbB receptor heterodimer
(Figure 2C, lower row, white arrows). In untreated MDA-HER2
cells, PS2-TAT is equally distributed within the cytoplasm
(Figure 2C, upper row).
PS2-TAT blocks the EGF-induced migration of
EGFR/c-erbB-2-positive MDA-HER2 cells
Since PLC-g1 is a key player in the EGF-mediated induction of
tumour cell migration, we next analysed the migratory behaviour
of PS1/2-TAT-treated MDA-HER2 cells by using the three-
dimensional collagen matrix migration assay combined with
computer-assisted cell tracking. Untreated MDA-HER2 cells
displayed a mean spontaneous locomotory activity of about
66.074.9% that was significantly increased by EGF (100ngml
 1)
treatment to 80.573.4% (Po0.0001, Figure 3a) and that is
congruent to previously published data (Dittmar et al, 2002).
The EGF (100ngml
 1)-induced migration of MDA-HER2 cells was
significantly and permanently blocked by PS2-TAT (2mM) treat-
ment of about 75% to solely 24.875.3% (Po0.0001; Figure 3a).
Similar results were obtained with the PLC-g1 inhibitor U73122
(2mM) that was used as a control. Here, the locomotory activity was
reduced to 19.474.4% (Po0.0001; Figure 3a). These results clearly
indicate that the observed reduced migration of PS2-TAT-treated
MDA-HER2 cell is attributed to PS2-TAT-mediated PLC-g1
inhibition. In contrast to PS2-TAT, the inhibitory capacity of
PS1-TAT was rather moderate (Figure 3a). In the first 7–8h, the
locomotory activity of EGF- and PS1-TAT-treated MDA-HER2
cells was solely reduced to the control level of untreated MDA-
HER2 cells. After that time, the locomotory activity increased
steadily, finally reaching the locomotory activity level of EGF-
treated MDA-HER2 cells. In mean, we estimated a locomotory
activity of PS1-TAT- and EGF-treated MDA-HER2 cells of about
66.977.5%. In addition to the determination of the average
locomotory activity of the MDA-HER2 cell population, we also
analysed the time locomotion of single MDA-HER cells, which
represents the time of how long a single cell has migrated during
the whole observation time. This is a crucial parameter that has to
be determined when investigating cell migration since changes in
the locomotory activity of a cell population in response to a
stimulus or inhibitor could be attributed either to a change in the
total number of migrating cells or to a change in the total time of
locomotion of single cells or to a combination of both modi
operandi. The results of the time locomotion are displayed in a
Box-Plot diagram, whereby the Box-Plot indicates the distribution
of the single values with 50% of all values lying within the Box. It
can be clearly deduced from Figure 3b that the EGF (100ngml
 1)-
induced time locomotion of MDA-HER2 cells is markedly
decreased by 2mM PS2-TAT treatment. While EGF-stimulated
MDA-HER2 cells locomoted 72–97% of the observed time period,
PS2-TAT treatment reduced the locomoting time to 0–38%.
Similar results were obtained using the PLC-g1 inhibitor U73122
(Figure 3B). Here, we observed a time locomotion of 0–36% and
the total number of EGF-induced MDA-HER2 cells was decreased
to 50.0715.3%. In agreement with the slightly reduced EGF-
induced migration of PS1-TAT-treated MDA-HER2 cells, we
determined a weakly decreased locomoting time of 58–82%
(Figure 3B).
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Figure 3 The EGF-induced migration of MDA-HER2 cells is permanently
blocked by PS2-TAT. Cell migration was analysed by using the three-
dimensional collagen matrix assay combined with computer-assisted cell
tracking. (A) The mean locomotory activity of EGF (100ngml
 1)-treated
MDA-HER2 cells was significantly (*¼Po0.0001) reduced by about 75%
by PS2-TAT (2mM) treatment. Similar results were achieved by U73122
(2mM) that was used as a control. In contrast to this, PS1-TAT (2mM)
showed a rather marginal inhibition of the EGF (100ngml
 1)-induced
migration of MDA-HER2 cells. The graph represents the mean locomotory
activity of treated and untreated MDA-HER2 cells of four independent
experiments (120 cells). (B) The Box-Plot diagram represents the time
locomotion of single MDA-HER2 cells. PS2-TAT (2mM) but not PS1-TAT
(2mM) treatment resulted in a markedly reduced time locomotion of EGF
(100ngml
 1)-treated MDA-HER2 cells. U73122 (2mM) treatment yielded
comparable results. Results were obtained from four independent
experiments (120 cells).
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cells
In addition to the cell migration data indicating a long-term
inhibitory capacity of PS2-TAT, we performed an XTT prolifera-
tion assay to investigate whether long-term PS2-TAT (2mM)
treatment of MDA-HER2 cells also influenced the proliferation
rate of this cells. Owing to the above-mentioned limitations of
U73122 and its worse solubility in aqueous solutions, the U73122-
dependent cell proliferation of MDA-HER2 cells was not
determined. The results are summarised in Figure 4 and it could
be clearly deduced from the graph that long-term PS2-TAT
treatment resulted in a decreased proliferation rate of MDA-HER2
cells. Compared to the proliferation rate of control cells, the
growth of PS2-TAT-treated MDA-HER2 cells was reduced by about
55% after 4 days and 50% after 7 days, respectively. In accordance
with the weakly influenced EGF-induced migration of MDA-HER2
cells, we observed a slightly reduced proliferation of PS1-TAT-
treated MDA-HER2 cells. Here, we estimated a proliferation rate of
about 91% after 4 days and 88% after 7 days as compared to the
proliferation of control cells.
DISCUSSION
In the present study, we generated protein-based PLC-g1 inhibitors
consisting of PLC-g1-SH2 domains fused to the TAT leader
sequence as highly specific inhibitors to block PLC-g1 tyrosine
phosphorylation, thereby inhibiting the EGF-induced migration of
EGFR/c-erbB-2-positive breast cancer cells. The adaptor protein
PLC-g1 was chosen as a target due to its pivotal role in the EGF-
dependent migration and invasiveness of tumour cells mediated by
EGFR and c-erbB-2 signalling. Epidermal growth factor-induced
PLC-g1 activation contributes to the engagement of actin-
modifying enzymes including gelsolin (Chen et al, 1996), resulting
in the rearrangement of the actin cytoskeleton, thereby promoting
cell migration by increasing the fraction of cells in a motility-
permissive morphology (Wells et al, 1999). In addition to this, it
was recently demonstrated by Dittmar et al (2002) that the
induction and maintenance of the EGF-mediated cell migration of
EGFR/c-erbB-2-positive breast cancer cells is driven by the c-erbB-
2-dependent EGFR/c-erbB-2 heterodimer signalling, thereby mod-
ulating the PLC-g1 kinetics.
Two protein-based PLC-g1 inhibitors were generated consisting
of either one (PS1-TAT) or two (PS2-TAT) PLC-g1-SH2 domains,
whereby the PS1-TAT protein contains the N-terminal SH2-
domain of PLC-g1. The PLC-g1 N-terminal SH2 domain was
chosen since it binds to the c-erbB-2 tyrosine residue 1248, which
in turn plays a key role in PLC-g1 activation (Dittmar et al, 2002).
The treatment of MDA-HER2 cells with the PS2-TAT protein
resulted in a reduced PLC-g1 tyrosine phosphorylation, a markedly
decreased EGF-induced cell migration as well as a reduced
proliferation of MDA-HER2 cells. The confocal laser scanning
microscopy results show that activation of the EGFR/c-erbB-2
heterodimer results in a translocation of the PS2-TAT to the
plasma membrane where it is found to be colocalised with the
EGFR/c-erbB-2 heterodimer complex. Together with the Western
blot data showing a reduction in PLC-g1 tyrosine phosphorylation,
we conclude that the PS2-TAT protein most likely competes with
the native PLC-g1 protein for binding to the activated EGFR/c-
erbB-2 heterodimer, thereby inhibiting PLC-g1 activation.
However, it remains unclear as to why PS1-TAT showed no or
solely a weak PLC-g1 inhibition, although PS1-TAT should bind to
c-erbB-2 tyrosine residue 1248 for which a pivotal role in PLC-g1
activation has been described (Dittmar et al, 2002). Since we
observed a slightly decreased PLC-g1 tyrosine phosphorylation in
the solely EGFR-positive MDA-MB-468-NEO cell line (data not
shown), we presume that the underlying reasons for the
noninhibitory capacity of PS1-TAT are likely attributed to the
different binding affinities of the PS1-TAT protein to the
appropriate activated erbB receptor. The finding that both PLC-
g1 SH2 domains are necessary for a complete blockade of PLC-g1
activation, thereby inhibiting cell migration, are consistent with
the findings of Kassis et al (1999), who reported that the
expression of a dominant-negative PLCz domain, consisting of
both SH2, the SH3 and an inhibitory (I) domain, resulted in a
reduction of the invasiveness of the EGFR/c-erbB-2-positive cell
line MDA-MB-362. However, protein expression in eukaryotic cells
requires an efficient DNA transfection and protein expression
system. In contrast to this, the chosen TAT-transduction system
overcomes the limitations that could occur in case of DNA
transfection such as low transfection efficiency. The TAT-
transduction technique allows a fast and concentration-dependent
delivery of TAT fusion proteins into nearly 100% of cells, where
they remain for 48h until their degradation (Schwarze and Dowdy,
2000; Abu-Amer et al, 2001). Using the TAT protein transduction
technology, protein purification can be performed regardless of
renaturation or folding since misfolding enhances the uptake of
the protein into the cells where it gets folded correctly (Nagahara
et al, 1998). In addition to this, this approach also overcomes the
limitations that could occur in case of U73122 usage since this
inhibitor has to be dissolved in organic solvents and tend to
precipitate when transferred to aqueous solutions, thereby losing
its inhibitory capacity. Furthermore, U73122 also blocks PLC-b
activity (Rossler et al, 1998) and therefore possible side effects of
both U73122 as well as the organic solvent could not be excluded.
Long-term PS2-TAT treatment of MDA-HER2 cells resulted in a
markedly decreased EGF-driven migration as well as in a reduced
proliferation rate of these cells. These results clearly indicate that
PS2-TAT has a long-term inhibitory capacity, which in turn is a
prerequisite for a possible therapeutic relevance. Several in vivo
studies using TAT fusion proteins as active compounds have
already been described. Harada et al have demonstrated success-
fully the antitumour effect of a TAT-oxygen-dependent degrada-
tion-caspase-3 fusion protein, which is specifically stabilised and
activated in hypoxic tumour cells. Intraperitoneal injection of this
TAT fusion protein into a tumour-bearing mouse resulted in a
reduction of the tumour size (Harada et al, 2002). Besides the
usage of TAT fusion proteins as anticancer drugs, a TAT-bcl-xl
fusion protein was successfully used as a neuroprotective
substance in order to prevent neuronal death after ischaemic
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Figure 4 PS2-TAT long-term treatment decreases the proliferation of
MDA-HER2 cells. MDA-HER2 cells were permanently incubated within the
presence of 2mM PS1/2-TAT. Cell proliferation was measured by XTT
assay on days 0, 4 and 7. Compared to control cells, the proliferation of
PS2-TAT (2mM)-treated MDA-HER2 cells was reduced by about 50%.
PS1-TAT (2mM) treatment showed a rather marginal effect. Each value is
the mean7s.e. of quadruplicate data.
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sbrain injury (Cao et al, 2002) or transient focal ischaemia (Kilic
et al, 2002) in mice.
In conclusion, our data show that protein-based PLC-g1
inhibitors are not only potent PLC-g1 inhibitors but also possess
antitumour effects on EGFR/c-erbB-2-positive breast cancer cells
due to the inhibition of both proliferation and migration.
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